Data collection from patients treated in the diabetes department, in Pitié-Salpêtrière hospital, and adressed for a one-day hospitalization to assess cardiovascular comorbidities.

Coronary Artery Calcification

Retrospective : data from medical record Prospective : vital statuts from follow-up phone call

Data collection

Diabetology department, Pitié-Salpêtrière hospital

Toe-brachial Index and Coronary Calcification in Type 1 and 2 Diabetes

Association Between Toe-brachial Index and Coronary Calcification in Asymptomatic Patients With Type 1 and Type 2 Diabetes Mellitus

Toe-brachial index has been performed by a clinician nurse of the diabetology department, using a fully automatic photoplethysmographic device, Systoe®. Three measurements have been performed on the first toe of both foot : the first one to permit blood volumeflow, and the mean of the others has been recorded to define toe blood pressure. Toe-brachial index is the ratio of toe systolic blood pressure and brachial systolic blood pressure. The lowest value of toe-brachial index between the right and the left side is used. Toe-brachial index cut-off is 0.7.

Vital statuts will be collected by the investigator during a follow-up phone call.

Coronary artery calcification score has been measured using a cardiac-gated multidetector computerized tomography (semi-automated software using the calcium score developed by Agatston. It is defined as a lesion with a density above 130 Hounsfield units, and with an area above 1mm². Coronary artery calcification score was the amount of the score of left main artery, left anterior descending artery, left circumflex artery and right coronary artery. Standardized categories are used to describe coronary artery calcification score : 0 for absence of calcified plaque, 1 to 10 for minimal plaque, 11 to 100 for mild plaque, 101 to 400 for moderate plaque, and >400 for severe plaque. Age, sex and race-specific percentiles of coronary artery calcification score are also performed, using the methodology described in the Multi-Ethnic Study of Atherosclerosis (validated only for patients between 45 and 84 years old). A score ≥75th percentile defines a high cardiovascular risk.

Stress myocardial perfusion tomography was realized using a cycloergometer until maximal heart rate (stopped in case of clinical symptoms or ECG abnormalities). Abnormal stress myocardial perfusion tomography is defined by a perfusion defect on stress images on at least one of the 17 anatomical region of the left ventricle, and absent on rest images.

Coronary angiography has been performed in the cardiology department, in Pitié-Salpêtrière hospital. A coronary stenosis is defined by a stenosis≥ 50%.

Assistance Publique - Hôpitaux de Paris

Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.
Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c >8%) or hypothyroidism (thyroid-stimulating hormone >1.5 upper normal limit), renal failure (creatinine clearance <30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study.

Familial Hypercholesterolemia

Program for identification of individuals at high and very high risk of cardiovascular complications

Chelyabinsk State Medical Academy

Russian Research and Production Center

Novosibirsk Research Institute of Internal Medicine, Institute of Internal Medicine Siberian Branch of the Russian Academy of Medical Sciences

Saint-Petersburg State University and North-West State Medical University n.a. I.I.Mechnikov

Samara State Medical University

Russian Familial Hypercholesterolemia Registry

Prospective Russian Study Evaluating the Extent of Underdiagnosed and Undertreated of Familial Hypercholesterolaemia in the Population

Assessment of carotid atherosclerosis will be performed with the use of carotid duplex scanning.
Presence and severity of aortic valve stenosis will be evaluated with echocardiography.
Exercise radionuclide myocardial perfusion imaging with single-photon emission computed tomography (SPECT) will be used for the diagnosis of myocardial ischemia in patients suspicious for CHD.

Genetic testing for FH-causing mutation in patients with probable and definite FH

Contribution in the formation of the Russian Health Ministry legislative acts concerning significance of FH as a socially and medically important disease with appropriate management strategies.

Incidence of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization procedures (cardiac, carotid, or peripheral), hospitalizations due to unstable angina pectoris or heart failure, all-cause mortality, diabetes in participants without baseline diabetes, new or recurrent cancers.

Clinical and diagnostic significance of Dutch Lipid Clinic Network criteria and Simon Broome Registry criteria for the diagnosis of FH in Russia.

Marat Vladislavovich Ezhov (MV Ezhov, MD, PhD, DMSc)

Leading Researcher, MD, DMSc

Russian Cardiology Research and Production Center

Pfizer

Amgen

AstraZeneca

Patients on atorvastatin treatment hospitalised due to cardiovascular events

Cardiovascular Disorders

Patients on atorvastatin treatment

Rio University Hospital

Euroclinic Private Hospital

Evagelismos General State Hospital

Gennimatas General State Hospital

Konstantopoulio General Hospital

General State Hospital

University Hospital

Hippokration General Hospital

Sismanogleio General State Hospital

Tzannion General State Hospital

424 Military Hospital

Papageorgiou Hospital

Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events

A Multicenter, Open-label, 30-week Observational Clinical Study to Examine the Progress of Patients After Leaving the Cardiology Clinic or Unit Due to Acute Cardiovascular Event.

The evaluation of atorvastatin treatment to all patients with cardiovascular events and separate the two subgroups (diabetes type II patients with metabolic syndrome) in order to achieve the level of lipids (LDL-C, HDL-C, T-CHOL) plasma blood

Achieving the level of lipids (LDL-C, HDL-C, T-CHOL) in blood plasma of patients in the atorvastatin dosage: those who received the 40 mg dose and those who received a dose of 80 mg

The investigation of compliance to treatment (days without taking medication, changing the time of intake) and its correlation with the achievement of target lipid levels (LDL-C, HDL-C, T-CHOL) in blood plasma of the studied patients

Safety evaluation by adverse events reporting

The reporting of hematological and biochemical tests where conducted at each hospital center, as part of their standard clinical practice

The determination of dyslipidemia class it belongs to each patient in order to assess the efficacy of atorvastatin administered.

carotid stenosis/triglyceride

Toe-brachial Index and Coronary Calcification in Type 1 and 2 Diabetes

Russian Familial Hypercholesterolemia Registry

Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events

Carotid Atherosclerosis Regression at Magnetic Resonance Assessment.

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası